Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis
- 206 Downloads
The aim of this study was to determine the performance of antibodies against mutated citrullinated vimentin (anti-MCV) in comparison with antibodies to cyclic citrullinated peptides (anti-CCP) in patients with rheumatoid arthritis (RA). Serum levels of anti-MCV and anti-CCP were determined in 193 patients with RA and 332 controls, and sensitivity and specificity were calculated. In a separate analysis of 86 patients, the anti-MCV levels were compared to disease activity. Sensitivity of anti-MCV versus anti-CCP was 71.5 and 69.4%, specificity was 81.3 and 97.6%, respectively. The ROC curves showed higher specificity and an advantage of anti-CCP. In seronegative RA patients the sensitivity of anti-MCV was superior over anti-CCP. Anti-MCV positivities also occurred in systemic lupus erythematosus and Sjoegren’s syndrome. In a subgroup of 86 RA patients we found a significant correlation between anti-MCV and disease activity. Anti-MCV appears to be an important marker for the diagnosis of RA, and correlates also with disease activity.
KeywordsAnti-mutated citrullinated vimentin Rheumatoid arthritis Inflammatory rheumatic diseases Sensitivity and specificity
American College of Rheumatology
Anti-citrullinated peptides antibodies
Antibodies against cyclic citrullinated peptide
Antibodies against mutated citrullinated vimentin
Antibodies against Sa-antigen
Disease activity score
Enzyme linked immuno sorbent assay
Human leucocyte antigen
Receiver operating characteristics curve
Systemic lupus erythematosus
D.I. Fabian (Orgentech Company) provided the kits for analysis. Funding for this work was given by Ludwig Boltzmann Cluster (Rheumatology, Balneology and Rehabilitation), Institute of Rheumatology of the Kurstadt Baden, Austria.
Conflict of interest statement
The authors declare that they do not have competing interests.
- 14.Rönnelid J, Mullazehi M, Mathsson L (2007) Differential prognostic impact of autoantibodies and inflammation markers in early rheumatoid arthritis. In: Conrad K, Chan EKL, Fritzler MJ, Sack U, Shoenfeld Y, Wiik AS (eds) Autoantigens, Autoantibodies, Autoimmunity, vol 5. Report on the 8th Dresden Symposium on autoantibodies. 12–15 September 2007, pp 389–400Google Scholar